Abstract

Exertional heat illness (EHI) and malignant hyperthermia (MH) are life threatening conditions associated with muscle breakdown in the setting of triggering factors including volatile anesthetics, exercise, and high environmental temperature. To identify new genetic variants that predispose to EHI and/or MH, we performed genomic sequencing on a cohort with EHI/MH and/or abnormal caffeine-halothane contracture test. In five individuals, we identified rare, pathogenic heterozygous variants in ASPH, a gene encoding junctin, a regulator of excitation-contraction coupling. We validated the pathogenicity of these variants using orthogonal pre-clinical models, CRISPR-edited C2C12 myotubes and transgenic zebrafish. In total, we demonstrate that ASPH variants represent a new cause of EHI and MH susceptibility.

The genetic cause(s) of malignant hyperthermia and exertional heat illness are unknown in approximately 30% of cases. To address this barrier, the authors performed genome sequencing on a large cohort of cases, identifying rare variants in ASPH, a gene encoding junctin, and validating them in animal and cell models.

Details

Title
Variants in ASPH cause exertional heat illness and are associated with malignant hyperthermia susceptibility
Author
Endo, Yukari 1   VIAFID ORCID Logo  ; Groom, Linda 2 ; Celik, Alper 3 ; Kraeva, Natalia 4 ; Lee, Chang Seok 5 ; Jung, Sung Yun 5 ; Gardner, Lois 6 ; Shaw, Marie-Anne 6 ; Hamilton, Susan L. 5 ; Hopkins, Philip M. 7   VIAFID ORCID Logo  ; Dirksen, Robert T. 2 ; Riazi, Sheila 4   VIAFID ORCID Logo  ; Dowling, James J. 8   VIAFID ORCID Logo 

 Hospital for Sick Children, Program for Genetics and Genome Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646) 
 University of Rochester, Department of Physiology, Rochester, USA (GRID:grid.16416.34) (ISNI:0000 0004 1936 9174) 
 Hospital for Sick Children, Centre for Computation Medicine, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646) 
 Malignant Hyperthermia Unit, Department of Anesthesia, Toronto General Hospital, Toronto, Canada (GRID:grid.417184.f) (ISNI:0000 0001 0661 1177) 
 Baylor College of Medicine, Department of Molecular Physiology and Biophysics, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X) 
 University of Leeds, Leeds Institute of Medical Research at St. James’s, Leeds, UK (GRID:grid.9909.9) (ISNI:0000 0004 1936 8403) 
 University of Leeds, Leeds Institute of Medical Research at St. James’s, Leeds, UK (GRID:grid.9909.9) (ISNI:0000 0004 1936 8403); Malignant Hyperthermia Unit, St. James’s University Hospital, Leeds, UK (GRID:grid.443984.6) (ISNI:0000 0000 8813 7132) 
 Hospital for Sick Children, Program for Genetics and Genome Biology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); Hospital for Sick Children, Division of Neurology, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646); University of Toronto, Department of Paediatrics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Molecular Genetics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2675830784
Copyright
© The Author(s) 2022. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.